STALE?Report written 13 days ago · at $1.17entry levels may be stale — re-check before acting

INO

MoonshotSMALL CAP

Inovio Pharmaceuticals, Inc. · NASDAQ · Healthcare / Biotechnology (Rare Disease)

$1.17

▼ 0.85%

MCap $121M

$1.17, -0.85% today — up +51.9% since the Aug 13 report's $0.77 on real regulatory de-risking: the late-cycle review completed with no new issues, all pre-licensure inspections finished (one minor observation, response submitted), and label negotiations began in September. The stock is now ABOVE the $0.95 July offering price for the first time since that raise, so the warrant overhang caps upside less than before — but there's also less margin of safety left if the Oct 30 read goes badly. This run means the old report's Base target ($1.40, +81.8% from $0.77) now offers only +19.7% remaining — a ~62pp base-decay distortion that this refresh exists to correct.

BusinessDNA immunotherapy · INO-3107 for recurrent respiratory papillomatosis — a single-asset PDUFA bet on Oct 30 (31 days out), now past a clean late-cycle review AND all pre-licensure inspections, with label negotiations underway; the Accelerated Approval eligibility question is still unresolved and cash runway into late Q1 2027 is the real clock

Thesis

The regulatory picture has cleanly improved since Aug 13: the FDA completed its late-cycle review of the INO-3107 BLA and finished all scheduled pre-licensure inspections (clinical, manufacturing, in-house testing, delivery device) with only one observation, already addressed; label negotiations began in September, and commercial prep continues with Syneos Health and MSLs engaging customers. The open question is unchanged — the Accelerated Approval eligibility issue flagged in the file acceptance letter still has no direct FDA comment as of the Sep 11 H.C. Wainwright conference. What's new and worth flagging honestly: a fresh survival check trips for the first time on this name. Cash funds operations only into late Q1 2027 (~5-6 months from today), and Inovio filed an active S-3 shelf on Jul 2, 2026 that it already tapped once for the $20M July offering — a follow-on raise before or shortly after the Oct 30 PDUFA is a real possibility. The +52% run since Aug 13 has already priced in much of the de-risking, so less reward is left on approval than the last report implied. This remains a single-asset binary at a ~$121M market cap — sized as ค่าขนม regardless of how clean the file looks.

📝 Primary Verdict · Core Holding

SPECULATIVEMoonshot

Late-cycle review and all pre-licensure inspections are now clean, which genuinely improves the odds — but the stock already ran +52% pricing much of that in, and a fresh survival check trips for the first time (runway to late Q1 2027, active shelf tapped once already). Turbo's entry rule reads -13.7% median return from report-price to catalyst (n=19), so Entry 1 is not preferred; prefer the $0.95-$1.05 zone. 2% ค่าขนม sizing — at the floor of the 2-5% band given the survival flag and single-asset concentration.

58

score / 100 ⓘ

⚡ Catalyst

⚖️ INO-3107 PDUFA Decision31 DAYS

FDA target action date for INO-3107 in adults with recurrent respiratory papillomatosis. Late-cycle review is complete and all pre-licensure inspections (clinical, manufacturing, in-house testing, delivery device facility) have finished with only one observation, already addressed; label negotiations began September 2026. This is the whole thesis. Note: the Oct 27-28 FOMC meeting lands just 2 days before this PDUFA, adding macro noise right ahead of the binary.

Oct 30, 2026

🤝 Accelerated-Approval Eligibility MeetingBEFORE PDUFA

The FDA's file acceptance letter flagged a potential review issue on whether INO-3107 qualifies under the Accelerated Approval pathway. As of the Sep 11, 2026 H.C. Wainwright conference, the FDA still had not directly commented on eligibility despite Inovio raising it; the company continues to believe it meets the requirements. No date published — genuinely undated, ahead of the Oct 30 PDUFA.

~Oct 2026

🎯 Entry Point

Entry 1

$1.17

Current price — up +52% since Aug 13 on clean regulatory progress. Per the turbo entry rule, median return from report-price anchor to catalyst is -13.7% (n=19); not preferred as the first moveค่าขนม only

Entry 2PREFERRED

$0.95–1.05

Pullback toward the July offering price — preferred per the -13.7% anchor-to-catalyst entry rule, better risk into a 31-day carryIf dips

Entry 3

$0.80

Deep dip back toward pre-de-risking levels — would suggest a bad signal from the AA eligibility question or a surprise raiseDeep dip

✅ Take Profit

TP1

Base — standard-pathway approval at the Oct 30 PDUFA readout itself (31 days out); the specific driver is FDA approval as a discrete binary event following a clean late-cycle review and fully-passed inspections, materially de-risked versus the pooled 30d lane baseline (P75 12.2% / P90 25.9%) which mostly reflects continuous, non-binary catalysts

$1.6

+36.8%

TP2

Bull — approval plus Accelerated Approval eligibility confirmed

$2.6

+122.2%

TP3 🌙

Moon — approval, AA pathway, and a credible launch ramp echoing the RETA template · 2027

$4.2

+259%

🔴 Stop Loss

Tight Stop

Wider than the fda_decision catalystType's medianMAE (-18.4%, n=10) per the stop rule — a tighter stop would risk firing on ordinary pre-PDUFA volatility

$0.84

-28.2%

Hard Stop

Below the deep-dip level; would imply the market is pricing a CRL or a distressed raise

$0.68

-41.9%

Risk / Reward

Entry 1 to hard stop vs TP2 (Bull)

2.9 : 1

⚠ ⚠️ Below the 5:1 turbo target — a CRL gaps straight through any stop overnight, and this is now compounded by the newly-flagged survival risk (runway to late Q1 2027, active shelf already used once). Treat position sizing, not R/R, as the real risk control. True asymmetry sits in the Moon case (+259.0% vs -41.9% hard stop ≈ 6.2:1).

📅 Estimate Date

INO-3107 PDUFA Decision

Binary — approve vs CRL, now past a clean late-cycle review and completed inspections

Oct 30, 2026

approval = first commercial product

Accelerated-Approval Eligibility

Still no direct FDA comment as of Sep 11; no date published

~Oct 2026

informal meeting

FOMC Meeting

Lands 2 days before the PDUFA — macro overlay on the binary week

Oct 27-28, 2026

n/a

📈 Possible Up % — Scenario Spread

Bear

-63.2%

$0.43

Base

+36.8%

$1.6

Bull

+122.2%

$2.6

Moon

+259%

$4.2

← downsideupside →

🏛️ Fed / Macro Risk — MEDIUM

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook

The Fed hiked 25bp to 3.75-4.00% on Sep 16, 2026 (12-0), a hawkish surprise despite the earlier weak Jul payrolls print. Next FOMC is Oct 27-28, 2026 — just 2 days before the Oct 30 PDUFA, adding a macro event directly into the binary week. Higher rates raise up from LOW (Aug 13 report) given the newly-flagged survival risk: any follow-on raise now prices against a tighter financing backdrop.

Inflation

Aug CPI (released Sep 11): headline 3.4% YoY, core 2.4% YoY (cooler YoY), but MoM ran hot at +0.4% headline / +0.3% core on a gasoline spike — the kind of print that keeps the Fed hawkish and financing costs elevated for a cash-constrained small-cap biotech.

Sector Impact

A single-asset PDUFA outcome still dominates anything macro does to a ~$121M biotech. But with the survival check now tripped (runway to late Q1 2027, active shelf already used once), the Sep 16 hike and the Oct 27-28 FOMC sitting right before the PDUFA both matter more than they did in the Aug 13 report.

Summary

MEDIUM — up from LOW in the last report. The Oct 30 decision still dominates the price, but the freshly-identified survival flag means financing conditions (a real hike just landed, another FOMC lands 2 days pre-PDUFA) are no longer a background factor.

🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

RETA✅ GoodFeb 2023

+199%

in 2 days

FDA approval of lead asset in a rare disease

The structural template for a single-asset rare-disease approval re-rate, and the basis for the Bull/Moon cases. Caveat: RETA was materially larger with no open pathway question.

SRPT⚡ MixedJun 2023

-11%

in 2 days

Accelerated approval granted despite advisory controversy

Directly relevant to INO's open Accelerated Approval question: an AA grant does not guarantee a positive stock reaction if the label or conditions disappoint.

INO❌ BadJul 2026

-30%

in 2 days

$20M dilutive offering priced at $0.95

Same ticker, the realistic non-PDUFA downside path — the S-3 shelf behind that offering is the same one still active today, and the reason the survival flag is now tripped.

⚡ Optional Layer · Tactical Overlay

🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-28.2% / -45%) only when trading the earnings spot — not for the core holding (use the -28.2% / -41.9% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern

+51.9% since Aug 13 (de-risking-driven, ahead of the classic pre-PDUFA drift)Since mid-Sep 2026 on regulatory de-risking news; the classic 1-2 week pre-PDUFA drift has not yet begun

The +52% move since the Aug 13 report (from $0.77 to $1.17) on the clean late-cycle review and completed inspections IS the pre-run here — unusually early and news-driven rather than the classic 1-2 week pre-PDUFA drift, which likely still has room to build into Oct 30. fda_decision is a Tier-2 LEADER catalystType (medianExcessVsBenchPct +9.3pp vs the overall +2pp, gap +7.3, n=10) — a genuine tailwind worth citing.

🎲Historical Post-Catalyst Move

✅ Catalyst Winavg +200%

range: +100% to +300%· Feb 2023

Sub-$200M single-asset biotechs re-rate violently on approval because the entire equity is the one product. RETA (Feb 2023) gained 199% on its approval — the structural template, though RETA was a larger company with a cleaner file. fda_decision is also this lane's strongest Tier-2 catalystType on a relative basis (+9.3pp excess vs benchmark, n=10), a real tailwind for this setup.

❌ Catalyst Missavg -55%

range: -40% to -70%· Jul 2026

A CRL on a single-asset name with the survival flag now tripped (runway to late Q1 2027, shelf already used once) forces an immediate dilutive raise, so the drawdown compounds. INO's own -30% on the Jul 2026 offering shows how the market prices dilution here even without a CRL; a CRL-driven raise would be worse, and SRPT's mixed -11% reaction to an Accelerated Approval grant shows even a positive regulatory outcome can disappoint if the label or conditions fall short.

💼Spot Position Sizing

How the recommended % is derived

2%

of portfolio

Held at the floor of the 2-5% turbo band. fda_decision is a Tier-2 leader (+9.3pp vs overall +2, n=10) — a real tailwind — but the freshly-identified survival flag (runway to late Q1 2027, active shelf already tapped once) and single-asset concentration keep sizing conservative despite the favorable catalyst-type read and the cleaner file.

🛑Stop Loss · Spot Trade

Spot cut-loss levels — separate from the core holding

Before Catalyst

-28.2%($0.84)

A break below ~$0.84 ahead of Oct 30 would suggest the AA eligibility question or label negotiations went badly

After Catalyst (Bad Result)-45%

On a CRL, exit into the first liquidity — the follow-on raise is now more urgent given the tighter runway math, and the re-file clock runs in years

📎 Sources

https://www.investing.com/news/transcripts/inovio-at-hc-wainwright-conference-fda-review-and-launch-loom-93CH-4897818 https://www.fool.com/earnings/call-transcripts/2026/08/12/inovio-ino-q2-2026-earnings-call-transcript/https://www.gurufocus.com/news/9029857/inovio-pharmaceuticals-inc-ino-q2-2026-earnings-call-highlights-ino3107-on-track-for-pdufa-as-cash-runway-extends-into-2027 https://finance.yahoo.com/sectors/healthcare/articles/inovio-pharmaceuticals-shareholders-back-board-180245147.html https://stockanalysis.com/stocks/ino/https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001055726&type=S-3&dateb=&owner=include&count=40 https://www.federalreserve.gov/newsevents/pressreleases/monetary20260916a.htm https://www.bls.gov/news.release/cpi.nr0.htm https://www.federalreserve.gov/monetarypolicy/fomccalendars.htm

Generated 2026-09-29 · Not financial advice